- Home
- DWTX
as 11-21-2024 4:00pm EST
Stocks
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | ALPHARETTA |
| Market Cap: | 4.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 80.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.62 - $23.50 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest DOGWOOD THERAPEUTICS INC News
DWTX Breaking Stock News: Dive into DWTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
MT Newswires
11 days ago
Top Premarket Decliners
Zacks Small Cap Research
11 days ago
DWTX: Phase 2 Long COVID Results Expected Soon
Thomson Reuters StreetEvents
14 days ago
Q3 2024 Dogwood Therapeutics Inc Earnings Call
GuruFocus.com
14 days ago
Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ...
GlobeNewswire
15 days ago
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
GlobeNewswire
22 days ago
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
GlobeNewswire
23 days ago
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Compare DWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DWTX DOGWOOD THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.